BCI-215
Based on 4 publication(s) in Google Scholar
BCI-215 is a potent and tumor cell-selective dual specificity MAPK phosphatase (DUSP-MKP) inhibitor. BCI-215 has cytotoxicity for tumor cells but not normal cells.
For research use only. We do not sell to patients.
- Purity: 99.86%
- CAS No.: 1245792-67-9
- Formula: C22H22BrNO
- Molecular Weight:396.32
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Breast Cancer Compound Library
HY-L074
-
Phosphatase Inhibitor Library
HY-L081
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) BCI-215
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
RT-PCR
-
WB
-
Cell Imaging/Staining
Biological Activity
DUSP-MKP[1]
BCI-215 concentration-dependently increases pERK levels in DUSP-overexpressing cells with IC50 value in the micromolar range[1].
BCI-215 (1-20 μM; 6 hours) retains fibroblast growth factor hyperactivating and cellular DUSP6/MKP-3 and DUSP1/MKP-1 inhibitory activity but is nontoxic to zebrafish embryos and an endothelial cell line[1].
BCI-215 inhibits survival and motility of MDA-MB-231 human breast cancer cells but does not affect viability of cultured hepatocytes[2].
BCI-215 is completely devoid of hepatocyte toxicity up to 100 μM[2].
BCI-215 does not generate ROS in hepatocytes or in developing Zebrafish larvae.
BCI-215 (22 μM) has antimigratory and proapoptotic activities in breast cancer cells that correlate with induction of ERK phosphorylation[2].
BCI-215 (20 μM; 1 hour) induces mitogenic and stress signaling in cancer cells without generating ROS[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231 cells
-
Concentration:22 µM
-
Incubation Time:
-
Result:Caused apoptotic cell death at concentrations that induce ERK phosphorylation.
-
Cell Line:MDA-MB-231 cells
-
Concentration:20 µM
-
Incubation Time:1 hour
-
Result:Induced a stress response that is not dependent on oxidation.
Chemical Information
-
CAS No. 1245792-67-9
-
Appearance Solid
-
Molecular Weight 396.32
-
Formula C22H22BrNO
-
Color White to light yellow
-
SMILES
O=C1/C(C(NC2CCCCC2)C3=C1C=CC(Br)=C3)=C/C4=CC=CC=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep
A progenitor cell population contributes to prenatal injury repair and neonatal antimicrobial defense in the small intestine. [Abstract]2026 Jun 4;45(6):117503. PMID: 42241283 -
Cell Rep
Negative feedback regulation of MAPK signaling is an important driver of chronic lymphocytic leukemia progression. [Abstract]2023 Oct 3;42(10):113017. PMID: 37792532 -
Molecules
BCI-215, a Dual-Specificity Phosphatase Inhibitor, Reduces UVB-Induced Pigmentation in Human Skin by Activating Mitogen-Activated Protein Kinase Pathways. [Abstract]2022 Aug 25;27(17):5449. PMID: 36080217
BCI-215 purchased from MedChemExpress. Usage Cited in: Molecules. 2022 Aug 25;27(17):5449. [Abstract]
The cytotoxicity of the BCI-215 exposure in the B16F10 cells was assessed using a WST cell proliferation assay and 10 µM BCI-215 showed cytotoxic effects.
BCI-215 purchased from MedChemExpress. Usage Cited in: Molecules. 2022 Aug 25;27(17):5449. [Abstract]
Relative value of MITF mRNA. BCI-215 (1 μM) decreased the transcription of MITF modestly only at an early time point.
BCI-215 purchased from MedChemExpress. Usage Cited in: Molecules. 2022 Aug 25;27(17):5449. [Abstract]
Immunoblotting of MITF and Tyrosinase up to 6 h after a treatment with BCI-215 (1 μM).
BCI-215 purchased from MedChemExpress. Usage Cited in: Molecules. 2022 Aug 25;27(17):5449. [Abstract]
Fontana–Masson staining of ex vivo human cultured skin tissue treated with a 200 mJ/cm2 dose of UVB with or without the BCI-215 (100 nM) treatment.
-
Cancer Res Commun
2024 Dec 1;4(12):3165-3179. PMID: 39585085
Solvent & Solubility
DMSO : 33.33 mg/mL (84.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.83 mg/mL (2.09 mM); Clear solution
This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Korotchenko VN, et al. In vivo structure-activity relationship studies support allosteric targeting of a dual specificity phosphatase. Chembiochem. 2014 Jul 7;15(10):1436-45. [Content Brief]
[2]. Kaltenmeier CT, et al. A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity. J Pharmacol Exp Ther. 2017 Apr;361(1):39-50. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5232 mL | 12.6161 mL | 25.2321 mL | 63.0803 mL |
| 5 mM | 0.5046 mL | 2.5232 mL | 5.0464 mL | 12.6161 mL | |
| 10 mM | 0.2523 mL | 1.2616 mL | 2.5232 mL | 6.3080 mL | |
| 15 mM | 0.1682 mL | 0.8411 mL | 1.6821 mL | 4.2054 mL | |
| 20 mM | 0.1262 mL | 0.6308 mL | 1.2616 mL | 3.1540 mL | |
| 25 mM | 0.1009 mL | 0.5046 mL | 1.0093 mL | 2.5232 mL | |
| 30 mM | 0.0841 mL | 0.4205 mL | 0.8411 mL | 2.1027 mL | |
| 40 mM | 0.0631 mL | 0.3154 mL | 0.6308 mL | 1.5770 mL | |
| 50 mM | 0.0505 mL | 0.2523 mL | 0.5046 mL | 1.2616 mL | |
| 60 mM | 0.0421 mL | 0.2103 mL | 0.4205 mL | 1.0513 mL | |
| 80 mM | 0.0315 mL | 0.1577 mL | 0.3154 mL | 0.7885 mL |
BCI-215 Related Classifications
HY-121087 Related Classifications
Powered by Bioz